<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787657</url>
  </required_header>
  <id_info>
    <org_study_id>13852</org_study_id>
    <secondary_id>311941</secondary_id>
    <secondary_id>BF0703</secondary_id>
    <nct_id>NCT00787657</nct_id>
  </id_info>
  <brief_title>Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment</brief_title>
  <acronym>BEACON</acronym>
  <official_title>Betaferon Prospective Study on Adherence, Coping and Nursing Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The Study analyses the influence of selected factors on adherence to Betaferon treatment
           in patients with early multiple sclerosis (MS). The Investigator will document the
           relevant medical data regarding multiple sclerosis at every hospital visit, the patient
           will fill in two questionnaires at every visit: one about coping with the disease and
           the other about anxiety and depression.

        -  The Study particularly looks at the role of the support of the patient given by the
           multiple sclerosis nurses.The nurse will provide additional standardised information at
           start of treatment and will regularly phone the patient to ask standardised questions
           about the general condition with regard to the treatment, the disease and social
           support. At the end of the Study it will be assessed if the supportive measures and the
           standards in terms of adherence management in the hospital have some influence to
           increase long-term treatment adherence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients adhering to treatment</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of early treatment termination</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of study dropout</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of BL parameters, WCQ, HADS, RODQ</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WCQ (Ways of Coping Questionnaire)</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS (Hospital Anxiety and Depression Scale)</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RODQ (Risk of Dropout Questionnaire)</measure>
    <time_frame>Monthly over 6 months; every other month thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS (Expanded Disability Status Scale)</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1723</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis (RRMS)</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b (Betaseron, BAY86-5046)</intervention_name>
    <description>Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients after clinical events suggestive of MS according to SMPC) and patients with
        elapsing / Remitting Multiple Sclerosis (RRMS) within the first two years of diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients after first clinical event suggestive of multiple Sclerosis (MS) (according
             to SmPC) and patients with Relapsing / Remitting Multiple Sclerosis (RRMS) within the
             first two years of diagnosis.

        Exclusion Criteria:

          -  Contra-indications as indicated in Betaferon summary of Products Characteristics
             (SmPC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Bahrain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Libyan Arab Jamahiriya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bahrain</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Iran, Islamic Republic of</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Korea, Republic of</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Libyan Arab Jamahiriya</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Pakistan</country>
    <country>Portugal</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>Syrian Arab Republic</country>
    <country>Taiwan</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>Venezuela</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results based on ICH-E3.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinically Isolated Syndrome (CIS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

